Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.

about

Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q48627805

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@en

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@nl

type

Item

label

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@en

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@nl

prefLabel

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@en

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@nl

P1476

Impact of the oncogenic status ...... ed non-small cell lung cancer.

@en

P2093

Hiroaki Kuroda

http://www.w3.org/2001/XMLSchema#string

Noriaki Sakakura

http://www.w3.org/2001/XMLSchema#string

Tetsuya Mizuno

http://www.w3.org/2001/XMLSchema#string

Yukinori Sakao

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Tumor recurrence after complete resection for non-small cell lung cancer.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

P304

928-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYW094

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yasushi Yatabe

P577

2016-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27402797

http://www.w3.org/2001/XMLSchema#string